Samrat Pharmachem Ltd
SAMRATPHSamrat Pharmachem Ltd
SAMRATPHPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
19.76 | 1.96 | 0.24% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
31.17 | 3.55 | 1.31% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Samrat Pharmachem Limited is engaged in the production of pharmaceutical chemicals like Iodine salts and Bromine salts. The Company's finished products are used in various industries, including pharmaceuticals, chemicals, food, fertilizer and salt.
Peers
Compare with peersSolar Industries India Ltd
Linde India Ltd
Deepak Nitrite Ltd
Himadri Speciality Chemical Ltd
Sumitomo Chemical India Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 63.41 | 72.90 | 93.19 | 111.60 | 138.03 | 179.48 | 222.38 | 311.13 | 282.96 | 297.14 | ||||||||||
Raw Materials | 56.46 | 62.95 | 82.43 | 103.53 | 131.80 | 162.02 | 190.23 | 288.00 | 265.48 | 287.94 | ||||||||||
Power & Fuel Cost | 0.74 | 0.63 | 0.82 | 0.73 | 0.91 | 1.12 | 1.34 | 1.46 | 1.37 | |||||||||||
Employee Cost | 0.66 | 0.76 | 0.85 | 0.94 | 1.00 | 1.05 | 0.96 | 1.07 | 1.11 | |||||||||||
Selling & Administrative Expenses | 3.03 | 3.11 | 2.31 | 2.09 | 1.83 | 1.83 | 2.46 | 3.10 | 3.36 | |||||||||||
Operating & Other expenses | 1.12 | 1.60 | 0.58 | 0.67 | -4.70 | 4.35 | 2.52 | -6.92 | 7.79 | |||||||||||
EBITDA | 1.40 | 3.85 | 6.20 | 3.64 | 7.19 | 9.11 | 24.87 | 24.42 | 3.85 | 9.20 | ||||||||||
Depreciation/Amortization | 0.44 | 0.43 | 0.41 | 0.42 | 0.43 | 0.49 | 0.59 | 0.64 | 0.65 | 0.65 | ||||||||||
PBIT | 0.96 | 3.42 | 5.79 | 3.22 | 6.76 | 8.62 | 24.28 | 23.78 | 3.20 | 8.55 | ||||||||||
Interest & Other Items | 0.51 | 0.63 | 0.86 | 1.06 | 0.98 | 1.28 | 0.67 | 1.23 | 0.69 | 0.70 | ||||||||||
PBT | 0.45 | 2.79 | 4.93 | 2.16 | 5.78 | 7.34 | 23.61 | 22.55 | 2.51 | 7.85 | ||||||||||
Taxes & Other Items | 0.15 | 1.02 | 1.70 | 0.62 | 1.55 | 2.01 | 6.42 | 5.90 | 0.36 | 1.41 | ||||||||||
Net Income | 0.30 | 1.77 | 3.23 | 1.54 | 4.23 | 5.33 | 17.19 | 16.65 | 2.15 | 6.44 | ||||||||||
EPS | 0.97 | 5.73 | 10.45 | 4.98 | 13.69 | 17.25 | 55.64 | 53.89 | 6.96 | 20.84 | ||||||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.14 | 0.05 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
MaterialsCommodity Chemicals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Samrat Pharmachem Ltd | 59.18 | 1.96 | 0.24% |
Solar Industries India Ltd | 116.83 | 28.50 | 0.08% |
Linde India Ltd | 132.33 | 16.56 | 0.18% |
Deepak Nitrite Ltd | 45.91 | 7.72 | 0.27% |
Price Comparison
Compare SAMRATPH with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Sep 19, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Sep 22, 2022
Net profit of Samrat Pharmachem reported to Rs 2.66 crore in the quarter ended September 2024 as against net loss of Rs 0.19 crore during the previous quarter ended September 2023. Sales declined 12.00% to Rs 70.17 crore in the quarter ended September 2024 as against Rs 79.74 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales70.1779.74 -12 OPM %4.800.28 - PBDT3.690.39 846 PBT3.520.23 1430 NP2.66-0.19 LP Powered by Capital Market - Live
Samrat Pharmachem will hold a meeting of the Board of Directors of the Company on 14 November 2024.Powered by Capital Market - Live
Net profit of Samrat Pharmachem rose 239.34% to Rs 2.07 crore in the quarter ended June 2024 as against Rs 0.61 crore during the previous quarter ended June 2023. Sales rose 40.61% to Rs 80.82 crore in the quarter ended June 2024 as against Rs 57.48 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales80.8257.48 41 OPM %3.191.34 - PBDT2.980.91 227 PBT2.820.75 276 NP2.070.61 239 Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 20.45%, vs industry avg of 9.38%
Increasing Market Share
Over the last 5 years, market share increased from 0.15% to 0.24%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 6.9%, vs industry avg of 4.33%